The Effect of Propofol and Remifentanil Sequence on ED50 and ED95 of Rocuronium in Rapid Sequence Induction Anesthesia

• Status: Completed
• Trial end date: 2016-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Rapid sequence induction (RSI) is a well-known procedure to maintain a safe and rapid airway in patients especially at risk of aspiration. Propofol and rocuronium are generally used agents for RSI. However, the difficult airway scenarios are always valid for these patients, even without predictive signs of difficult airway. Therefore, it is important to decrease the rocuronium dose used in RSI to achieve a rapid recovery of a neuromuscular conduction with the aid of a reversal agent in case of difficult airway. The short acting opioids such as remifentanil may be helpful to reduce the dose of rocuronium in RSI.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ankara University
• Treatments: Anesthetics; Propofol; Remifentanil; Rocuronium

Criteria

Inclusion Criteria:

• American Society of Anesthesiologists (ASA) physical status I-II patients

• patients scheduled for elective surgery

Exclusion Criteria:

• suspected or known difficult airway

• a significant renal or hepatic dysfunction

• a known neuromuscular disease

• hypertension

• a known allergy to one of the drugs used in general anesthesia

• a body mass index lower than 18.5 kg/m2 or higher than 30 kg/m2

• intake of any medication that might interact with rocuronium

• patient refusal